Very fast, very potent tryptamine psychedelic. A serotonergic agonist with affinity rank 5-HT1A >> 5-HT2A (5-HT1A is the primary high-affinity target, ~300-fold over 5-HT2A). O-demethylated by CYP2D6 to bufotenine and an MAO substrate. Found in Bufo alvarius (Sonoran toad) venom. Risks: extreme intensity, transient hypertension, rare serotonin toxicity when MAOI-combined.
Half-Life & Elimination Curve (IN: 27m)
Elimination (IN)
0×t½0h100%
1×t½27m50%
2×t½54m25%
3×t½1.35h12.5%
4×t½1.8h6.3%
5×t½2.25h3.1%
Elimination t½27m (IN)
Rate Constant (ke)1.54 h⁻¹
97% Washout (5×t½)2.25h
Dosing Guidelines
Inhaled (INH): Typical 12 mg (Range: 6–20 mg)
Intranasal (IN): Typical 8 mg (Range: 1–12 mg)
Target Organ Systems
nervous
Notes
PubChem CID 1832. PK: Rucker 2024 (PMID:38616411) verbatim "the mean terminal elimination half-life was <27 min" (Tmax ~8–10 min) for intranasal BPL-003 5-MeO-DMT benzoate; authored as 0.45 h. 5-HT2A occupancy not authored — 5-HT2A is the weak target (5-HT1A primary) and its Ki is table-only (see AUTHORING_GAPS).